Ginkgo Bioworks (NYSE:DNA) Announces Quarterly Earnings Results, Misses Expectations By $0.21 EPS

Ginkgo Bioworks (NYSE:DNA) announced its quarterly earnings data on Thursday. The company reported ($1.45) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.24) by ($0.21), Zacks reports. Ginkgo Bioworks had a negative net margin of 188.00% and a negative return on equity of 49.23%. The firm had revenue of $38.84 million for the quarter, compared to analyst estimates of $38.95 million. Ginkgo Bioworks updated its FY 2025 guidance to EPS.

Ginkgo Bioworks Stock Down 20.4%

DNA stock traded down $2.31 during mid-day trading on Friday, reaching $9.00. The company had a trading volume of 2,955,726 shares, compared to its average volume of 1,305,470. Ginkgo Bioworks has a one year low of $5.00 and a one year high of $17.58. The stock has a market capitalization of $532.50 million, a P/E ratio of -1.44 and a beta of 1.53. The stock’s 50-day simple moving average is $12.60 and its two-hundred day simple moving average is $10.89.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on DNA shares. Wall Street Zen lowered Ginkgo Bioworks from a “hold” rating to a “sell” rating in a research report on Saturday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Ginkgo Bioworks in a research note on Wednesday, October 8th. Cowen reissued a “buy” rating on shares of Ginkgo Bioworks in a report on Friday, August 8th. Finally, BTIG Research lifted their price target on shares of Ginkgo Bioworks from $6.00 to $9.00 and gave the company a “sell” rating in a report on Monday, August 25th. One equities research analyst has rated the stock with a Buy rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, Ginkgo Bioworks presently has a consensus rating of “Reduce” and an average target price of $9.00.

Insider Activity at Ginkgo Bioworks

In related news, insider Steven P. Coen sold 5,609 shares of the stock in a transaction dated Wednesday, October 1st. The shares were sold at an average price of $15.00, for a total value of $84,135.00. Following the sale, the insider owned 5,503 shares of the company’s stock, valued at $82,545. This trade represents a 50.48% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 9.72% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the company. Shay Capital LLC grew its holdings in Ginkgo Bioworks by 6.2% in the 2nd quarter. Shay Capital LLC now owns 19,382 shares of the company’s stock worth $218,000 after buying an additional 1,124 shares in the last quarter. California State Teachers Retirement System boosted its position in Ginkgo Bioworks by 10.0% during the 2nd quarter. California State Teachers Retirement System now owns 26,674 shares of the company’s stock worth $300,000 after acquiring an additional 2,426 shares during the period. Raymond James Financial Inc. bought a new position in shares of Ginkgo Bioworks in the second quarter worth $29,000. Daiwa Securities Group Inc. bought a new position in shares of Ginkgo Bioworks in the second quarter worth $71,000. Finally, Headlands Technologies LLC increased its holdings in shares of Ginkgo Bioworks by 30.0% during the second quarter. Headlands Technologies LLC now owns 40,818 shares of the company’s stock valued at $459,000 after purchasing an additional 9,408 shares during the period. Institutional investors own 78.63% of the company’s stock.

About Ginkgo Bioworks

Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.